# Forensic Dossier: Study Forensics: Novel cholesterol drug dramatically lowers LDL but cardiovascular outcomes unknown

**Run ID:** `mc2_study-forensics-032_claude_haiku_bf1b25`  
**Task:** study-forensics-032 | study_forensics | medium | study_forensics  
**Timestamp:** 2026-04-06T16:25:22.597906+00:00  
**Task Family:** mechanism_vs_evidence  
**Trap Type:** biomarker_sold_as_clinical_benefit  
**Ambiguity:** low  

## Executive Summary

**Agents tested:** Claude Haiku
**Winner:** Claude Haiku — **40.0/100** (margin: 0.0)
**Failure modes:** wrong_answer
**Forensic flags:** 2
**Consistency findings:** 5
**Answer convergence:** all agents agree

## Score Matrix

| Agent | Correctness | Support Strength | Structural Reaso | Assumption Disci | Uncertainty Hand | Alternative Hypo | Self Monitoring  | Insight Depth | Mechanism Qualit | Communication Ef | **Total** |
|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| Claude Haiku | 0.0/30 | 0.7/8 | 4.8/8 | 4.8/6 | 3.9/6 | 5.2/6 | 5.6/8 | 8.0/8 | 0.0/10 | 8.5/10 | **40.0/100** |

## Study Forensics Audit

### Claude Haiku

**Classification:** `overclaim` [x] (gold: `mechanism_vs_evidence`)
**Finding Recall:** 100%
**Matched Findings:** mechanism_not_demonstrated, conclusion_exceeds_results
**Extra Findings:** evidence_matches_claim, cautious_scope_control, none_or_minor, decorative_uncertainty, correlation_as_causation

## Reasoning Integrity Audit

### Claude Haiku
**Classification:** Correct and well-supported
**Load-bearing steps:** 0 / 6

## Mechanism Analysis

### Claude Haiku
| Aspect | Status |
|--------|--------|
| Concept named | :x: none |
| Mechanism described | :x: (0 sentence(s)) |
| Grounded to case | :x: (0 sentence(s)) |

**Missing:** concept not named, mechanism not described, mechanism not grounded to case data

## Grounding Audit

### Claude Haiku
Conclusion claims: 1
- Direct support: 0
- Indirect support: 0
- Unsupported: 1
- Contradicted: 0

**Unsupported claims:**
- "overclaim"


## Forensic Flags

### Claude Haiku

- **[MAJOR]** `well_reasoned_wrong`: Wrong answer but structured reasoning — may have a subtle logic error
  - `final_answer`: "overclaim"
- **[MODERATE]** `unsupported_conclusion_claims`: 1/1 conclusion claims lack step support
  - `final_answer`: "overclaim"


## Evidence Map

### Claude Haiku

**Correctness:** 0.0/30
  - (+) `final_answer`: "overclaim"
    _Agent's answer for correctness check_
  - Note: No match (got: overclaim)

**Support Strength:** 1.2/8
  - (+) `final_answer`: "overclaim"
    _Conclusion grounded by reasoning chain_
  - Note: Support classification: 0 load-bearing, 0 supporting, 0 mentioned / 6
  - Note: Reasoning graph confirms conclusion grounding

**Structural Reasoning:** 4.8/8
  - (+) `steps[5]`: "Evaluated the accelerated approval claim: based on surrogate endpoints without outcome data, this represents a causal le"
    _Most informative reasoning step_
  - Note: 6 reasoning steps
  - Note: Low step utility: 0/6 steps contribute

**Assumption Discipline:** 4.8/6
  - (+) `assumptions[4]`: "LDL reduction is a validated surrogate marker for cardiovascular benefit, but surrogate benefit ≠ clinical benefit in al"
    _Most substantive assumption_
  - Note: 5/5 substantive assumptions

**Uncertainty Handling:** 3.9/6
  - (+) `uncertainties[2]`: "Whether the company's accelerated approval strategy is based solely on LDL data or includes other supportive evidence no"
    _Most substantive uncertainty_
  - (+) `confidence`: "confidence: 0.92"
    _Stated confidence level_
  - Note: 4 uncertainties (4 substantive)
  - Note: Confidence 0.92

**Alternative Hypothesis Quality:** 5.2/6
  - (+) `alternative_hypotheses[1]`: "mechanism_vs_evidence: The mechanism (LDL lowering) is demonstrated, but the clinical consequence (cardiovascular protec"
    _Most substantive alternative hypothesis_
  - Note: 2 alternative hypotheses considered
  - Note: 1/2 include rejection reasoning

**Self Monitoring Quality:** 5.6/8
  - (+) `self_check[3]`: "Did I miss any caveats in the original text? The text mentions 'more research needed' implicitly (4-year outcomes trial)"
    _Most substantive self-verification step_
  - Note: 5 self-check items
  - Note: Self-check quality: 0 deep, 5 arithmetic, 0 fluff

**Mechanism Quality:** 0.0/10
  - Note: Neither names concept nor explains mechanism

**Communication Efficiency:** 8.5/10
  - Note: Signal density: 0.73, 520 words

**Insight Depth:** 8.0/8
  - (+) `(output text)`: "a 12-week phase 2 trial with surrogate endpoints only identified the claims:"
    _Insight 'surrogate endpoint' matched (exact)_
  - Note: Key insights: 2 full / 2


## Failure Analysis

### Claude Haiku

**CRITICAL:**
- **Wrong Answer** `[HIGH CONFIDENCE]`: Answer does not match expected 'mechanism_vs_evidence'
  - `final_answer`: "overclaim"
  - _Impacts: correctness_

**MAJOR:**
- **Wrong Answer** `[HIGH CONFIDENCE]`: Study classification incorrect: expected 'mechanism_vs_evidence', detected 'overclaim'
  - `final_answer`: "overclaim"
  - _Impacts: correctness_


## Consistency & Grounding Audit

### Claude Haiku

- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 1 has low overlap with final answer (1/16 content words)
  - `key_claims[0]`: "The core overclaim: executives describe LDL reduction as 'cardiovascular protection' and claim the d"
- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 2 has low overlap with final answer (0/15 content words)
  - `key_claims[1]`: "Surrogate endpoint problem: LDL is a validated risk factor, but reduction in a risk factor does not "
- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 3 has low overlap with final answer (0/19 content words)
  - `key_claims[2]`: "Premature acceleration: pursuing accelerated approval based on 12-week surrogate data, with outcomes"
- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 4 has low overlap with final answer (0/13 content words)
  - `key_claims[3]`: "No decorative uncertainty: the report does not indicate that executives qualified their claims with "
- **[NOTE]** `[HEURISTIC]` `weak_alternative`: Alternative hypothesis 1 is stated without rejection reasoning
  - `alternative_hypotheses[0]`: "correlation_vs_causation: The claim that LDL reduction will 'transform outcomes' assumes causation f"


## Agent Profiles

### Claude Haiku (claude-haiku-4-5-20251001)
**Parse OK:** True | **Latency:** 10433ms

**Final Answer:** overclaim

**Confidence:** 0.92

**Assumptions:**
- The press report accurately represents what company executives stated
- The trial design is as described: 12-week duration, LDL and liver safety endpoints only
- No cardiovascular outcome data were collected during this Phase 2 trial
- The company is indeed pursuing accelerated approval based on surrogate endpoints
- LDL reduction is a validated surrogate marker for cardiovascular benefit, but surrogate benefit ≠ clinical benefit in all contexts

**Reasoning Steps:**
1. Identified the primary evidence: 65% LDL reduction in a 12-week Phase 2 trial with surrogate endpoints only
2. Identified the claims: executives called results a 'major breakthrough in cardiovascular protection' and said the drug would 'transform outcomes' for high-risk patients
3. Recognized the gap: surrogate endpoint (LDL) vs. claimed clinical benefit (cardiovascular protection, heart attack/stroke prevention)
4. Noted the temporal issue: no cardiovascular outcomes data exist; outcomes trial won't report for 4+ years
5. Assessed whether LDL reduction alone justifies claims about cardiovascular protection: while LDL is a validated risk factor, reduction in LDL does not guarantee reduction in cardiovascular events in all populations or drug classes
6. Evaluated the accelerated approval claim: based on surrogate endpoints without outcome data, this represents a causal leap from biomarker to clinical benefit

**Key Claims:**
- The core overclaim: executives describe LDL reduction as 'cardiovascular protection' and claim the drug will 'transform outcomes' without any cardiovascular event data
- Surrogate endpoint problem: LDL is a validated risk factor, but reduction in a risk factor does not guarantee clinical benefit; this is a well-known pitfall in drug development
- Premature acceleration: pursuing accelerated approval based on 12-week surrogate data, with outcomes trial 4+ years away, represents confidence in a causal link that has not been demonstrated
- No decorative uncertainty: the report does not indicate that executives qualified their claims with appropriate caveats about the lack of outcome data

**Alternative Hypotheses:**
- correlation_vs_causation: The claim that LDL reduction will 'transform outcomes' assumes causation from a surrogate marker without outcome evidence
- mechanism_vs_evidence: The mechanism (LDL lowering) is demonstrated, but the clinical consequence (cardiovascular protection) is asserted without evidence

**Uncertainties:**
- Whether the drug class has prior evidence supporting LDL-to-outcome translation (e.g., if this is a novel mechanism, the assumption is weaker)
- The exact language used by executives—whether they explicitly claimed cardiovascular benefit or if this is paraphrased
- Whether the company's accelerated approval strategy is based solely on LDL data or includes other supportive evidence not mentioned in this summary
- The baseline cardiovascular risk profile of the trial population and whether 65% LDL reduction is clinically meaningful in this specific group

**Self-Verification:**
- Did I confuse surrogate endpoints with clinical endpoints? No—the distinction is clear and appropriate here.
- Did I assume LDL reduction is never predictive of cardiovascular benefit? No—I acknowledged LDL is a validated risk factor, but noted that surrogate benefit ≠ clinical benefit.
- Did I fabricate missing data? No—the report explicitly states no cardiovascular events were tracked.
- Did I miss any caveats in the original text? The text mentions 'more research needed' implicitly (4-year outcomes trial), but this is decorative uncertainty because executives still made strong claims about cardiovascular protection.
- Is this a fair characterization of overclaim? Yes—claiming 'cardiovascular protection' and 'transformed outcomes' based on a surrogate endpoint without outcome data is a textbook example of overclaim.

**Dimension Scores:**
- Correctness: 0.0/30 `..........`
- Support Strength: 0.7/8 `..........`
- Structural Reasoning: 4.8/8 `######....`
- Assumption Discipline: 4.8/6 `########..`
- Uncertainty Handling: 3.9/6 `######....`
- Alternative Hypothesis Quality: 5.2/6 `########..`
- Self Monitoring Quality: 5.6/8 `#######...`
- Insight Depth: 8.0/8 `##########`
- Mechanism Quality: 0.0/10 `..........`
- Communication Efficiency: 8.5/10 `########..`


## Final Verdict

**Solo run: Claude Haiku** scored **40.0/100**.

**Best per dimension:**
- Correctness: Claude Haiku (0.0/30)
- Support Strength: Claude Haiku (0.7/8)
- Structural Reasoning: Claude Haiku (4.8/8)
- Assumption Discipline: Claude Haiku (4.8/6)
- Uncertainty Handling: Claude Haiku (3.9/6)
- Alternative Hypothesis Quality: Claude Haiku (5.2/6)
- Self Monitoring Quality: Claude Haiku (5.6/8)
- Insight Depth: Claude Haiku (8.0/8)
- Mechanism Quality: Claude Haiku (0.0/10)
- Communication Efficiency: Claude Haiku (8.5/10)

**Latency vs Quality:**

| Agent | Latency | Score | Points/sec |
|-------|---------|-------|------------|
| Claude Haiku | 10.4s | 40.0/100 | 3.8 |

Failure modes observed: wrong_answer.
